Meloxicam

is prescribed to treat:

• Osteoarthritis and rheumatoid arthritis pain • Various related conditions in the pain management category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Meloxicam (Mobic) is a non-steroidal anti-inflammatory drug used mainly for osteoarthritis and rheumatoid arthritis. Its once-daily dosing and reputation for relative COX-2 preference have made it one of the most prescribed NSAIDs in outpatient practice, though that reputation is more qualified than it is usually presented.

Mechanism of Action

Meloxicam inhibits cyclooxygenase, reducing prostaglandin synthesis and therefore inflammation, pain sensitisation, and fever. Its distinguishing claim is preferential COX-2 inhibition — greater activity against the inducible enzyme responsible for inflammation than against the constitutive COX-1 that protects gastric mucosa, supports renal perfusion, and enables platelet aggregation.

The important qualifier is that this preference is dose-dependent and only partial. At lower doses meloxicam behaves in a relatively COX-2-preferential way and produces less gastrointestinal injury than a fully non-selective agent. At higher doses the selectivity substantially erodes and it behaves much like any other NSAID. Patients and prescribers who treat meloxicam as inherently gentle at any dose are relying on a property it only partly has.

It is not a true selective COX-2 inhibitor in the way celecoxib is, and it offers no protection at all against the renal and cardiovascular effects of the class, which follow from COX-2 inhibition itself rather than from COX-1.

Clinical Use

Meloxicam suits chronic inflammatory arthritis well, because once-daily dosing provides steady coverage and improves adherence in conditions treated for years. It is less useful for acute pain, since its slow onset — peak effect takes hours — makes it a poor choice when rapid relief is wanted, where ibuprofen or naproxen work faster.

The long half-life that enables once-daily dosing also means the drug accumulates over several days to steady state, and correspondingly clears slowly. A patient who develops a problem does not become NSAID-free the next day.

Because it is prescribed rather than bought over the counter, meloxicam has one practical advantage: it appears on the medication list. A great deal of NSAID harm comes from over-the-counter use nobody records, and a prescribed NSAID is at least visible for interaction checking and monitoring. That visibility is worth something in a patient who is going to take an NSAID regardless.

For osteoarthritis specifically, topical NSAIDs deserve consideration before oral therapy in knee and hand disease. They achieve therapeutic local concentrations with a fraction of the systemic exposure, and in older patients that difference is clinically meaningful. The knee osteoarthritis article covers the full range of non-surgical options, and our musculoskeletal team manages long-term arthritis care.

Monitoring and Follow-Up

Regular use warrants periodic kidney function checks, blood pressure monitoring — NSAIDs raise it and blunt most antihypertensives — and hemoglobin, since occult gastrointestinal blood loss can cause iron deficiency anemia before overt bleeding appears. Liver enzymes are worth including in longer-term monitoring.

Gastroprotection with a proton pump inhibitor such as pantoprazole is appropriate in patients over 65, those with prior ulcer or bleeding, and anyone taking a corticosteroid, anticoagulant, or SSRI alongside. The reduced gastrointestinal risk at lower meloxicam doses does not eliminate the need for this in genuinely high-risk patients.

The cardiovascular warning applies to meloxicam as to the rest of the class: NSAIDs increase myocardial infarction and stroke risk, an effect appearing within weeks rather than only after years, and amplified by higher doses. They also cause sodium and fluid retention and can precipitate decompensation in heart failure. The MedlinePlus meloxicam entry covers prescribing detail, and the FDA NSAID safety communication sets out the class warning.

Onset and expectation deserve attention because they cause avoidable dissatisfaction. Meloxicam accumulates over several days, so a patient who takes the first dose expecting the relief an over-the-counter analgesic provides within an hour will conclude it does not work. Explaining that the drug reaches full effect over roughly a week, and asking the patient to judge it at that point rather than on day one, converts a large proportion of apparent non-responders into responders. It also discourages the common workaround of adding another NSAID on top in the first few days, which doubles the risk without adding benefit.

Special Populations

In older adults, all NSAID risks are amplified and renal reserve is reduced; meloxicam's once-daily convenience should not obscure that. In chronic kidney disease, NSAIDs are generally avoided.

In pregnancy, meloxicam is avoided from 20 weeks because of fetal renal effects and oligohydramnios, and contraindicated in the third trimester. Patients with aspirin-exacerbated respiratory disease can develop severe bronchospasm with any NSAID. Prior peptic ulcer, active bleeding, and recent coronary bypass surgery are contraindications. In cirrhosis, NSAIDs risk variceal bleeding, kidney injury, and fluid retention, and acetaminophen at a reduced ceiling is the safer analgesic.

Once-daily dosing has one further implication worth stating. Because the drug is designed to hold a steady level rather than to peak and fade, taking an extra dose on a bad day does not produce extra relief within any useful timeframe — it simply raises the level and the risk. Patients who want breakthrough relief are better served by adding acetaminophen, which acts quickly through a different mechanism, than by doubling the meloxicam. The same logic applies in reverse: a missed dose does not need to be made up with a double dose the following day.

When to Contact Your Doctor

Seek urgent care for black or tarry stools, vomiting blood or coffee-ground material, severe abdominal pain, chest pain, or sudden weakness or difficulty speaking. Report reduced urine output, new swelling, or rapid weight gain, which suggest fluid retention or kidney injury. Increasing breathlessness needs evaluation, and wheezing after a dose may indicate NSAID-sensitive asthma.

Because meloxicam is taken daily for chronic conditions, it is worth reviewing periodically whether it is still needed and whether a topical agent, a different analgesic, or a disease-modifying approach would serve better than indefinite oral NSAID use.

To review your arthritis treatment, address side effects, or discuss alternatives to a daily NSAID, contact us or schedule a visit.